ClinicalTrials.gg
RecruitingNCT03567889NeoDREAMUpdated Dec 17, 2025

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

A Phase 3 interventional study of Daromun and Surgery in Melanoma Stage IIIB, Melanoma Stage IIIC and Melanoma Stage IIID, sponsored by Philogen S.p.A.. Recruiting at 37 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Philogen S.p.A. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
246th of 1,750
186 · median 37
Started
2018
with 96 others
Phase 3
107 of 2,050
10 open now
Primary completion
2027-12
later than 261 of 433 live
Registered
1,374th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 246th largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 97 that started in 2018, is one of 107 in phase 3, reaches primary completion later than 261 of the 433 other live ones, and was the 1,374th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Read the detailed description

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of Daromun neoadjuvant intratumoral treatment followed by surgery and adjuvant therapy versus surgery and adjuvant therapy in clinical stage III B/C/D melanoma patients. 186 patients will be randomized in a 1:1 ratio to receive Daromun treatment followed by surgery and adjuvant therapy (Arm 1) or surgery and adjuvant therapy (Arm 2).

In both arms, follow-up for assessing recurrence-free survival will be performed up to five years after randomization. Survival information will also be collected in the following year (up to six years in total after randomization).

This is an open-label study, so there is no blinding.

Patients who successfully complete the screening evaluations and are eligible for participation in the study will be enrolled and randomly assigned (1:1) to two parallel treatment arms: Daromun plus surgery and adjuvant therapy (Arm 1) or surgery and adjuvant therapy (Arm 2).

To ensure a balance across treatment groups, stratified randomization with permuted block will be used and separate randomization list for each subgroup (stratum) will be produced. Patients will be stratified on the basis of the following prognostic factors:

  • Stage of disease (3 levels): Stage IIIB vs. Stage IIIC vs Stage IIID
  • Planned post-surgical adjuvant therapy (2 levels): anti-PD-1 and other adjuvant therapies.

The primary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Primary endpoint of the study is RFS in a time-to-event analysis in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus the surgery plus adjuvant therapy control group (Arm 2). Analysis will be based on the "Intention To Treat" population.

The key secondary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant manner the overall survival (OS) of patients with resectable Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

For patients enrolled in both arms, local approved post-surgery adjuvant therapies (as part of the standard of care) are allowed and decided at the investigator's discretion. These include high-dose interferon- α2b, anti-CTLA-4 antibodies (e.g. Ipilimumab), anti-PD1 antibodies (e.g. Nivolumab, Pembrolizumab), targeted therapies (e.g. Dabrafenib + Trametinib), or other new local approved treatments.

03

Conditions studied

  • Melanoma Stage IIIB
  • Melanoma Stage IIIC
  • Melanoma Stage IIID

Browse trials for

Keywords

  • Melanoma Stage IIIB
  • Melanoma Stage IIIC
  • Melanoma Stage IIID
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of clinical stage IIIB, IIIC, and IIID (AJCC 8th edition) locoregional melanoma that is eligible for complete surgical resection of all (surgically resectable).
  2. Eligible subjects must have and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (≥ 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm.
  3. Prior anti-tumor treatment for the primary melanoma lesion, including surgery and approved treatments (e.g., radiotherapy, , BRAF/MEK inhibitors, etc.) is allowed. Before enrollment in the study, a of 6 weeks is required and toxicities from prior treatments should be resumed to Grade ≤1.
  4. Males or females, age ≥ 18 years.
  5. Performance Status/WHO Performance Status ≤ 1.
  6. of > 24 months.
  7. > 1.5 x 109/L.
  8. > 9.0 g/dL.
  9. > 100 x 109/L.
  10. Total ≤ 30 μmol/L (or ≤ 2.0 mg/dl).
  11. and AST ≤ 2.5 x the (ULN).
  12. Serum creatinine \< 1.5 x ULN.
  13. LDH serum level ≤ 1.5 x ULN.
  14. Documented negative test for , and . For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e. positive anti-HBsAg with not vaccination and/or positive anti-HBcAg Ab), negative serum HBV-DNA is also required.
  15. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) (CTCAE) (v4.03) Grade ≤ 1 unless otherwise specified above.
  16. All women of (WOCBP) must have negative pregnancy test results at the screening. WOCBP must be using, from the screening to three months following the last study drug administration, highly effective methods. WOCBP and effective contraception methods are defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence. Pregnancy test will be repeated at the safety visit (only WOCBP and only for patients in Arm 1).
  17. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  18. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  19. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria

  1. Uveal melanoma or mucosal melanoma
  2. Evidence of distant at screening.
  3. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except: cervical carcinoma in situ, curatively treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1), second primary melanoma in situ or any cancer curatively treated ≥ 5 years prior to study entry.
  4. Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  5. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  6. Inadequately controlled cardiac arrhythmias including atrial fibrillation.
  7. Heart insufficiency (> Grade II, (NYHA) criteria).
  8. ≤ 50% and/or abnormalities observed during baseline and Echocardiogram investigations that are considered as by the investigator.
  9. Uncontrolled hypertension.
  10. Ischemic peripheral vascular disease (Grade IIb-IV).
  11. Severe diabetic retinopathy.
  12. Active disease.
  13. History of organ allograft or stem cell transplantation.
  14. Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  15. Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies or any other constituent of the product.
  16. Breast feeding female.
  17. Anti-tumor therapy (except small surgery) within 4 weeks before enrollment.
  18. Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before enrollment.
  19. Planned administration of growth factors or immunomodulatory agents within 7 days before enrollment.
  20. Patient requiring or taking or other drugs on a long-term basis will be evaluated case by case with the Sponsor for inclusion/exclusion in the study. Limited use of corticosteroids to treat or prevent acute reactions is not considered an exclusion criteria.
  21. Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
  22. Previous enrolment and randomization in the same study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Daromun plus Surgery and Adjuvant therapy

    Arm-1 patients will follow these steps: 1. screening period, 2. 4-week open-label treatment period, 3. surgery within a maximum of 4 weeks, 4. adjuvant therapy.

    Drug: Daromun · Procedure: Surgery · Drug: Adjuvant therapy

  • Active comparator
    Surgery and adjuvant therapy

    Arm-2 patients will follow these steps: 1. Screening period, 2. direct surgery within 4 weeks from randomization, 3. adjuvant therapy.

    Procedure: Surgery · Drug: Adjuvant therapy

Interventions

  • Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks.

  • ProcedureSurgery

    Patients will receive surgery.

  • DrugAdjuvant therapy

    Patients will receive adjuvant therapy at the investigator's discretion following the surgery.

06

What researchers measure

Primary outcomes

  1. Recurrence Free Survival (RFS)

    Recurrence Free Survival (RFS) in a time-to-event analysis in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus the surgery and adjuvant therapy control group (Arm 2). Analysis will be performed for the "Intention To Treat" population.

    Time frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months.

Secondary outcomes

  1. Overall survival (OS)

    Overall survival (OS) in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery and adjuvant therapy (Arm 2), which will be evaluated in time to event analysis as key secondary endpoint.

    Time frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first, assessed up to 72 months.

  2. Recurrence free survival (RFS) as determined by the local investigator

    A sensitivity analysis to assess ascertainment bias will be performed on recurrence free survival. For this analysis the primary analysis definition of recurrence will be split into its two components and each will be analyzed separately. The first component/definition will be based on the unblinded assessment performed at the site - any new lesion detected by clinical evaluation which is confirmed by histopathology (biopsy or surgical specimen) and the second component/definition will be based on the assessment of a new lesion detected by allowed imaging modalities in a Blinded Independent Central Review and confirmed, wherever possible, by histological analysis. Each of these components will be analyzed separately using the same statistical model as the primary endpoint. Results from the two component analyses will be compared.

    Time frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months.

  3. Event-free survival (EFS)

    Event-free survival (EFS) defined as time from randomization to melanoma progression (irresectable stage III or stage IV disease), melanoma recurrence, treatment-related toxicity precluding surgery, treatment-related death, or melanoma-related death, whichever occurs first.

    Time frame: From date of randomization until the date of the first event as described above, assessed up to 60 months

  4. Adverse Events (AE)

    Percentage of Patients in Each Treatment Group with AEs, AEs with CTCAE grade ≥3

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the first follow-up visit (up to approximately 5 months).

  5. Immune-related Adverse Events (irAEs)

    Occurrence of immune-related Adverse Events (irAEs)

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months).

  6. Drug-Induced Liver Injury (DILI)

    Number of patients with Drug-Induced Liver Injury (DILI)

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months).

  7. Adverse Events of Special Interest (AESI)

    Number of patients with Adverse Events of Special Interest (AESI)

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months).

  8. Haematological/chemical Laboratory Abnormalities

    Percentage of Subjects with Haematological/chemical Laboratory Abnormalities

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months).

  9. Electrocardiogram (ECG) and echocardiogram (ECHO) abnormalities

    Percentage of participants with Electrocardiogram (ECG) and echocardiogram (ECHO) abnormality findings. Data about QT/QTc intervals will be collected and analysed for QT/QTc prolongation potentially caused by treatment.

    Time frame: 1) day 0-14 (screening) for both arm; 2) at week 5 (Safety assessment) only for arm 1.

  10. Physical examination

    Number of subjects with a clinically significant change from baseline in physical examination

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months)

  11. Concomitant medication

    Number of subject with concomitant medication

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months)

  12. Human anti-fusion protein antibodies (HAFA)

    Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF

    Time frame: 1) day 0-14 (screening) for arm 1; 2) at week 5 (Safety assessment) for Arm 1; 3) at week 12 (only first follow-up) for Arm 1.

  13. Vital signs (blood pressure)

    Number of subjects with a clinically significant change from baseline in vital signs (blood pressure) by visit

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months).

  14. Vital signals (heart rate)

    Number of subjects with a clinically significant change from baseline in vital signs (heart rate) by visit

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months)

  15. Vital signals (body temperature)

    Number of subjects with a clinically significant change from baseline in vital signs (body temperature) by visit

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of follow-up (up to approximately 60 months)

  16. Pathological responses

    Pathological responses (categorized into pCR, near-pCR, pPR, pNR, according to INMC criteria) assessed at time of surgical resection.

    Time frame: Assessed at the time of surgical resection of the tumor lesions.

Other outcomes

  1. Local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS)

    Local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) after randomization in the Daromun plus surgery and adjuvant therapy treatment group (Arm 1) versus surgery adjuvant therapy (Arm 2). LRFS is defined as survival free of loco-regional recurrence occurring at any time before systemic recurrence and other events are censored. DMFS is defined as survival free of systemic recurrence, including: 1) systemic recurrence outside the locoregional area at any time before or after locoregional relapse, 2) systemic recurrence with or without loco-regional relapse, or 3) death from cancer with no information on systemic recurrence.

    Time frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months

07

Study locations

26 of 37 sites recruiting
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
    Recruiting
    • Mahesh Seetharam, MD · Contact
    • Mahesh Seetharam, MD · Principal investigator
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UC Irvine Health-Chao Family Comprehensive Cancer Center
    Orange, California 92868-3201, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Jonathan Zager · Contact
    • Jonathan Zager, MD · Principal investigator
  • Winship Cancer Institute, Emory university
    Atlanta, Georgia 30322, United States
    Recruiting
    • Michael Lowe · Contact
    • Michael Lowe, MD · Principal investigator
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Anastasios Dimou, MD · Contact
    • Anastasios Dimou, MD · Principal investigator
  • Rutgers Cancer Institute, 195 Little Albany Street
    New Brunswick, New Jersey 08903, United States
    Recruiting
    • Adam Berger · Contact
    • Adam Berger, MD · Principal investigator
  • Ambulatory Care Center at NYC Langarone Health
    New York, New York 10016, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Memorial Sloan Kettering Cancer Center - Main Campus
    Ney York, New York 10065, United States
    Recruiting
    • Danielle Bello · Contact
    • Danielle Bello · Principal investigator
  • Duke University Medical Center - Duke Cancer Center
    Durham, North Carolina 27710, United States
    Recruiting
    • Georgia Beasley · Contact
    • Georgia Beasley · Principal investigator
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Claire Verschraegen · Contact
    • Claire Verschraegen, MD · Principal investigator
  • St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd.
    Easton, Pennsylvania 18045, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Penn State Cancer Institute
    Hershey, Pennsylvania 17033, United States
    Recruiting
    • Joseph Drabick · Contact
    • Joseph Drabick · Principal investigator
  • Fox Chase Cancer Center 333 Cottman Avenue
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • Jeffrey Farma · Contact
    • Jeffrey Farma, MD · Principal investigator
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030-4009, United States
    Recruiting
    • Hussein Tawbi · Contact
    • Hussein Tawbi · Principal investigator
  • Huntsman Cancer Institute, University of Utah 2000 Circle of Hope
    Salt Lake City, UT, Utah 84112, United States
    Recruiting
    • John Hyngstrom · Contact
    • John Hyngstrom · Principal investigator
  • VCU - McGlothlin Medical Education Center
    Richmond, Virginia 980037, United States
    Recruiting
    • Andrew Poklepovic · Contact
    • Andrew Poklepovic · Principal investigator
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
    Recruiting
    • José Luis Manzano Mozo · Contactjmanzano@iconcologia.net · +34615315823
    • José Luis Manzano Mozo · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08025, Spain
    Recruiting
    • Margarita Majem Tarruella · ContactMMajem@santpau.cat · +34935565638
    • Margarita Majem Tarruella · Principal investigator
  • Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • Eva Muñoz Couselo · Contactemunoz@vhio.net · +34932746085
    • Eva Muñoz Couselo · Principal investigator
  • Hospital Clinic Barcelona
    Barcelona, Barcelona 08036, Spain
    Recruiting
    • Josep Malvehy Guilera · Contactjmalvehy@clinic.cat · +34932275400
    • Josep Malvehy Guilera · Principal investigator
  • El Hospital Universitario De Gran Canaria Dr. Negrin
    Las Palmas de Gran Canaria, Canarie 35010, Spain
    Recruiting
  • Fundacion Onkologikoa Fundazioa
    Donostia / San Sebastian, Gipuzkoa 20014, Spain
    Recruiting
    • Karmele Mujika Eizmendi · Contactkmujika@onkologikoa.org · +34943328315
    • Karmele Mujika Eizmendi · Principal investigator
  • MD Anderson Cancer Center
    Madrid, Madrid 28033, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28041, Spain
    Recruiting
  • Hospital Universitario Regional de Málaga
    Málaga, Malaga 29010, Spain
    Recruiting
    • Elisabeth Pérez Ruiz · Contactelisaonco@gmail.com · +34951308130
    • Elisabeth Pérez Ruiz · Principal investigator
  • Hospital Clínico Universitario Virgen de la Arrixaca
    Murcia, Murcia 30120, Spain
    Recruiting
    • Pablo Cerezuela Fuentes · Contactpcerezuelaf@seom.org · +34968369387
    • Pablo Cerezuela Fuentes · Principal investigator
  • Hospital Universitario Virgen De La Macarena
    Seville, Sevilla 41009, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital General Universitario de Valencia
    Valencia, Spain
    Recruiting
    • Alfonso Berrocal Jaime · Contactberrocal.alf@gmail.com · +34963131800
    • Alfonso Berrocal Jaime · Principal investigator
  • Universitätsspital Basel
    Basel, Basel 4031, Switzerland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Istituto Oncologico della Svizzera Italiana
    Bellinzona, Bellinzona 6500, Switzerland
    Recruiting
    • Cristina Mangas · Contact
    • Cristina Mangas · Principal investigator
  • Insel Gruppe AG
    Bern, Canton of Bern 3010, Switzerland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpitaux Universitaires de Genève
    Geneva, Canton of Geneva 1205, Switzerland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kantonsspital St.Gallen
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
    Recruiting
    • Nikolaus Wagner · Contact
    • Nikolaus Wagner · Principal investigator
  • Universitätsspital Zürich (USZ)
    Zurich, Canton of Zurich 8091, Switzerland
    Recruiting
    • Egle Ramelyte · Contact
    • Egle Ramelyte · Principal investigator
08

References and documents

Publications

  • Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. PubMed 36648215 ↗
  • Miura JT, Zager JS. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncol. 2019 Nov;15(32):3665-3674. doi: 10.2217/fon-2019-0433. Epub 2019 Sep 20. PubMed 31538818 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Dec 2027, 111 months after the start.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's planned 111 months is above that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2018
First posted
Jun 26, 2018
StartActual
Sep 20, 2018
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2031
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03567889
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Sep 20, 2018
Primary completion
Dec 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Dec 17, 2025

Study contacts

Sheila Dakhel, PhD
Contact
sheila.dakhel@philogen.com
+41 (0) 43 544 88 02
Concetta Aulicino
Contact
regulatory@philogen.com
+39 0577 17 816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daromun

Start the discussion